Eli Lilly (NYSE: LLY) has become a Wall Street favorite, largely thanks to its blockbuster weight-loss and diabetes treatments, Mounjaro and Zepbound. But while these drugs drive a significant portion of the company’s revenue, there’s much more to its pipeline that investors should be watching closely.
The Power of GLP-1 Drugs and Their Market Influence
Mounjaro and Zepbound have been nothing short of game-changers for Eli Lilly. Together, they generated nearly $5 billion in sales in 2024, making Mounjaro the company’s top revenue driver while Zepbound quickly emerged as the fastest-growing segment.
The success of these drugs has propelled Lilly’s stock to new heights, often fluctuating based on investor sentiment toward GLP-1 treatments. With the broader pharmaceutical industry embracing these medications for weight management and diabetes, the company has positioned itself as a leader in a multi-billion-dollar market.
One important factor to consider is the rise of generic GLP-1 drugs. Though they lack FDA approval, their growing popularity has introduced pricing pressure. Lilly has responded by ramping up production and strategically pricing its products to maintain market dominance.
Beyond Weight Loss: Lilly’s Expanding Portfolio
While GLP-1 treatments get most of the attention, Eli Lilly’s other segments remain crucial to its long-term growth. The company is a major player in various therapeutic areas, including:
- Oncology, with multiple cancer treatments
- Immunology, covering plaque psoriasis and eczema
- Neuroscience, with a new focus on Alzheimer’s disease
One of the biggest developments to watch is Kisunla, a newly FDA-approved drug targeting Alzheimer’s disease. With the global market for Alzheimer’s treatments expected to quadruple to $31 billion by 2033, Kisunla presents a major growth opportunity.
Can Kisunla Challenge Existing Alzheimer’s Treatments?
Currently, Biogen and Eisai’s Leqembi leads the Alzheimer’s treatment space, but its commercial rollout has been underwhelming. Sales for the drug fell below expectations, with Eisai revising its revenue projections downward due to delays in the U.S. market.
This slow start creates an opening for Lilly. Kisunla has the potential to capture market share if it proves to be a more effective or accessible treatment. With limited competition and a massive patient population in need of solutions, Lilly’s bet on Alzheimer’s could be one of its most significant plays in years.
Stock Valuation: Is Lilly a Buy Right Now?
Despite strong fundamentals, Eli Lilly’s stock has seen valuation compression over the past year. Its forward price-to-earnings (P/E) ratio currently sits around 36—roughly 40% lower than a year ago.
The sell-off could be linked to concerns over generic GLP-1 drugs and pricing competition. However, Lilly’s aggressive manufacturing expansion and price adjustments suggest it is well-equipped to maintain dominance in this sector.
For investors looking beyond Mounjaro and Zepbound, Kisunla and Lilly’s broader pipeline present compelling reasons to keep an eye on the stock. With significant tailwinds in multiple areas, the company’s future may be more diversified than its recent GLP-1 success suggests.
